Canada's Zymeworks 2025 revenue rises 39%

Reuters03-02
Canada's Zymeworks 2025 revenue rises 39%

Overview

  • Biotechnology firm's 2025 revenue rose 39% yr/yr, driven by clinical milestones

  • Net loss for 2025 reduced by 34% compared to previous year

  • Company utilized $62.5 mln for share repurchases under current program

Outlook

  • Zymeworks expects adjusted operating expenses in 2026 to be 20% lower than 2025

  • Company anticipates regulatory milestone payments to fund operations beyond 2028

  • Zymeworks remains focused on timely execution of its novel strategy in 2026

Result Drivers

  • MILESTONE ACHIEVEMENTS - Revenue growth in 2025 was primarily driven by significant clinical and regulatory milestones achieved through collaborations with partners such as J&J and BeOne

  • ROYALTY TRANSITION - Transition of zanidatamab clinical activities to Jazz expected to reduce development-support revenue but increase royalty revenue over time

  • ROYALTY-BACKED FINANCING - $250 mln royalty-backed note financing with Royalty Pharma to support share repurchases and potential acquisitions

Company press release: ID:nGNXc8SC3P

Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q4 Basic EPS

-$0.55

Q4 Operating Expenses

$46.67 mln

Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 14 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the biotechnology & medical research peer group is "buy"

  • Wall Street's median 12-month price target for Zymeworks Inc is $34.00, about 46% above its February 27 closing price of $23.29

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment